ClinicalTrials.gg
CompletedNCT01997229Updated Jul 16, 2019Results posted

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

A Phase 3 interventional study of Eculizumab and Placebo in Refractory Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 114 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-16.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Enrollment
3rd of 13
125 · median 20
Started
2013
the only one that year
Phase 3
9 of 19
2 open now
Registered
2nd of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2013, is one of 9 in phase 3, and was the 2nd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.

03

Conditions studied

  • Refractory Generalized Myasthenia Gravis

Browse trials for

Keywords

  • Myasthenia Gravis
  • Eculizumab
  • safety
  • efficacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female patients ≥18 years old
  • Diagnosis of MG made by the following tests:

    1. Positive serologic test for anti-AChR Abs as confirmed at screening, and
    2. One of the following:

      1. History of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation, or
      2. History of positive anticholinesterase test, e.g. edrophonium chloride test, or
      3. Subject has demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician.
  • MGFA Clinical Classification Class II to IV at screening.
  • MG-ADL total score must be ≥6 at screening and Randomization (Day 1).
  • Subjects who have:

    1. Failed treatment with at least two agents. Or,
    2. Failed treatment with at least one immunosuppressive agent and require chronic plasma exchange or IVIg

Key Exclusion Criteria:

  • History of thymoma or other neoplasms of the thymus
  • History of thymectomy within 12 months prior to screening
  • MGFA Class I or MG crisis at screening (MGFA Class V)
  • Use of rituximab within 6 months prior to screening
  • Use of IVIg or PE within 4 weeks prior to Randomization (Day 1)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Biological/Vaccine: Eculizumab; Induction phase: 3 vials of study drug (equivalent to 900 mg of eculizumab) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (equivalent to 1200 mg of eculizumab) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (equivalent to 1200 mg of eculizumab) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).

    Biological: Eculizumab

  • Placebo comparator
    Placebo

    Placebo contains the same buffer components without the active ingredient; Induction phase: 3 vials of study drug (placebo) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (placebo) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (placebo) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).

    Drug: Placebo

Interventions

  • BiologicalEculizumab

    Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)

    In the Worst-Rank analysis, the 125 total patients were ranked from best outcome (rank/score of 1) to worst outcome (rank/score of 125).

    Time frame: End of study (Week 26)

07

Results

Posted Feb 7, 2018

Participant flow

Participant flow — Overall Study
MilestoneEculizumabPlacebo
Started6263
Completed5761
Not completed52

Outcome measures

PrimaryMyasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)

In the Worst-Rank analysis, the 125 total patients were ranked from best outcome (rank/score of 1) to worst outcome (rank/score of 125).

Time frame:
End of study (Week 26)
Reported as:
Least squares mean · scores on a scale
Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)
scores on a scaleEculizumabPlacebo
Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)56.6 ± 4.5368.3 ± 4.49
Statistical analysis
  • Eculizumab vs Placebo · ANCOVA · p = 0.0698 · Mean difference (net): -11.7 · 95% CI -24.33 to 0.96

Adverse events

Collected over 26 weeks (Study Period) + 8 weeks (Follow-up Period for subjects who discontinued the Study Period or completed the Study Period but did not enroll in the ECU-MG-302 extension trial). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab0/62 (0%)9/62 (14.5%)52/62 (83.9%)
Placebo0/63 (0%)18/63 (28.6%)53/63 (84.1%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventEculizumabPlacebo
Myasthenia gravisNervous system disorders5/628/63
PyrexiaGeneral disorders2/620/63
Upper respiratory tract infectionInfections and infestations0/622/63
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/620/63
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/620/63
LymphopeniaBlood and lymphatic system disorders1/620/63
Myasthenia gravis crisisNervous system disorders1/620/63
Intestinal perforationGastrointestinal disorders1/620/63
BacteraemiaInfections and infestations1/620/63
DiverticulitisInfections and infestations1/620/63
Most frequent other events
Showing 10 of 19
Most frequent other events
EventEculizumabPlacebo
HeadacheNervous system disorders10/6212/63
Upper respiratory tract infectionInfections and infestations10/6210/63
NasopharyngitisInfections and infestations9/6210/63
NauseaGastrointestinal disorders8/629/63
DiarrhoeaGastrointestinal disorders8/628/63
Back painMusculoskeletal and connective tissue disorders5/626/63
ContusionInjury, poisoning and procedural complications5/622/63
DizzinessNervous system disorders5/625/63
MyalgiaMusculoskeletal and connective tissue disorders5/622/63
Oral herpesInfections and infestations5/620/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)EculizumabPlaceboTotal
Mean47.5 ± 15.6646.9 ± 17.9847.2 ± 16.80
Sex: Female, Male
Sex: Female, Male(Participants)EculizumabPlaceboTotal
Female414182
Male212243
08

Study locations

114 sites
  • University of Alabama
    Birmingham, Alabama 35233, United States
  • University of California San Francisco-Fresno
    Fresno, California 93720, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of California-Irvine
    Orange, California 92868, United States
  • University of California Davis Health System
    Sacramento, California 95765, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • University of Florida Health Science Center
    Jacksonville, Florida 32209, United States
  • University of Miami School of Medicine
    Miami, Florida 33136, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Medical Associates of North Georgia
    Canton, Georgia 30114, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Iowa College of Medicine
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University School Of Medicine
    Baltimore, Maryland 21287-0876, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Lahey Clinic Inc.
    Burlington, Massachusetts 01805, United States
  • Wayne State University School of Medicine
    Detroit, Michigan 48201, United States
  • Las Vegas Clinic
    Las Vegas, Nevada 89145, United States
  • Buffalo General Hospital
    Buffalo, New York 14203, United States
  • Hospital For Special Surgery/New York Presbyterian Hospital Cornell Campus
    New York, New York 10021, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Carolinas Healthcare System
    Charlotte, North Carolina 28207, United States
  • Duke University Health System
    Durham, North Carolina 27705, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02905, United States
  • Wesley Neurology Clinic
    Cordova, Tennessee 38018, United States
  • Vanderbilt Medical Center
    Nashville, Tennessee 37232, United States
  • UT Southwestern
    Dallas, Texas 75390, United States
  • Methodist Neurological Institute
    Houston, Texas 77030, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05405, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Hospital Italiano
    Ciudad Autonoma, Buenos Aires 1181, Argentina
  • Instituto de Investigaciones Neurologicas Raul Carrea, FLENI
    Ciudad Autonoma, Buenos Aires C1428AQK, Argentina
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • AZ Sint-Lucas - Campus Sint-Lucas
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Hospital Mãe de Deus
    Porto Alegre, Rio Grande Do Sul 90110-270, Brazil
  • Faculdade de Medicina do ABC
    Santo André, Sao Paulo Postal Code: 09060-650, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José do Rio Preto, Sao Paulo 15090-000, Brazil
  • HUCFF-UFRJ - Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro
    Rio De Janeiro, 21941-913, Brazil
  • UNIFESP - Universidade Federal de São Paulo
    São Paulo, 04037-002, Brazil
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Montreal Neurological Institute
    Montreal, Quebec H3A 2B4, Canada
  • Vseobecna fakultni nemocnice v Praze
    Praha, Prague 120 00, Czechia
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • Århus Universitetshospital
    Aarhus C, 8000, Denmark
  • Rigshospitalet
    København Ø, 2100, Denmark
  • Helsingin yliopistollinen keskussairaala
    Helsinki, 00290, Finland
  • Neuro NEO Oy
    Turku, 20520, Finland
  • CHU de Nice Hôpital Pasteur 2
    Nice Cedex 3, Alpes Maritimes 06202, France
  • Groupe Hospitalier Pellegrin - Hôpital Pellegrin
    Bordeaux Cedex, Gironde 33000, France
  • Hopital Roger Salengro - CHU Lille
    Lille Cedex, Nord 59037, France
  • Hopital Neurologique Pierre Wertheimer
    Bron cedex, Rhone 69677, France
  • LMU-Campus Innenstadt
    Muenchen, Bayern 80336, Germany
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • Navy Hospital of Athens
    Athens, 11521, Greece
  • General Hospital of Thessaloniki "G. Papanikolaou"
    Thessaloniki, 57010, Greece
  • Jahn Ferenc Del-Pesti Korhaz
    Budapest, 1204, Hungary
  • Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin. Közp.
    Szeged, 6725, Hungary
  • Policlinico di Catania
    Catania, 95123, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milano, 20133, Italy
  • Azienda Ospedaliera Universitaria "Federico II"
    Napoli, 80131, Italy
  • Ospedale San Camillo IRCCS
    Padova, 35128, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • Umberto I Pol. di Roma-Università di Roma La Sapienza
    Roma, 00161, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Azienda Ospedaliera Sant'Andrea - Università di Roma La Sapienza
    Roma, 00189, Italy
  • Ospedale Santa Chiara
    Trento, 38122, Italy
  • Chiba University Hospital
    Chiba-shi, Chiba-Ken 260-8677, Japan
  • Kyushu University Hospital
    Fukuoka-shi, Fukuoka-Ken 812-8582, Japan
  • Sapporo Medical University Hospital
    Sapporo-shi, Hokkaido 060-8543, Japan
  • Hanamaki General Hospitals
    Hanamaki-shi, Iwate-Ken 025-0075, Japan
  • NHO Sendai Medical Center
    Sendai-shi, Miyagi-Ken 983-8520, Japan
  • NHO Nagasaki Kawatana Medical Center
    Kawatana, Nagasaki-Ken 859-3615, Japan
  • Nagasaki University Hospital
    Nagasaki-shi, Nagasaki-Ken 852-8501, Japan
  • Kinki University Hospital
    Osakasayama-shi, Osaka-Fu 589-8511, Japan
  • Osaka University Hospital
    Suita-shi, Osaka-Fu 565-0871, Japan
  • Toho University Ohashi Medical Center
    Meguro-ku, Tokyo-To 153-8515, Japan
  • Yamaguchi University Hospital
    Ube-shi, Yamaguchi-Ken 755-8505, Japan
  • Severance Hospital, Yonsei University Health System
    Seoul, 120-752, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 136-705, Korea, Republic of
  • Seoul Metropolitan Government Seoul National University
    Seoul, 156707, Korea, Republic of
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • Leiden Universitair Medisch Centrum
    Leiden, 2333 ZA, Netherlands
  • Maastricht University Medical Center
    Maastricht, 6229 HX, Netherlands

Showing the first 100 of 114 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT; MG Study Group. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013 Jul;48(1):76-84. doi: 10.1002/mus.23839. Epub 2013 Apr 30. PubMed 23512355 ↗
  • Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum In: Lancet Neurol. 2017 Dec;16(12):954. doi: 10.1016/S1474-4422(17)30377-0. PubMed 29066163 ↗
  • Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis. Front Neurol. 2021 Nov 2;12:696385. doi: 10.3389/fneur.2021.696385. eCollection 2021. PubMed 34795626 ↗
  • Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F; REGAIN Study Group. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve. 2021 Dec;64(6):662-669. doi: 10.1002/mus.27422. Epub 2021 Oct 14. PubMed 34590717 ↗
  • Nowak RJ, Muppidi S, Beydoun SR, O'Brien FL, Yountz M, Howard JF Jr. Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Front Neurol. 2020 Nov 24;11:556104. doi: 10.3389/fneur.2020.556104. eCollection 2020. PubMed 33329303 ↗
  • Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF Jr; REGAIN Study Group. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology. 2021 Jan 26;96(4):e610-e618. doi: 10.1212/WNL.0000000000011207. Epub 2020 Nov 23. PubMed 33229455 ↗
  • Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr; REGAIN study group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol. 2020 Aug;7(8):1327-1339. doi: 10.1002/acn3.51121. Epub 2020 Jul 22. PubMed 32700461 ↗
  • Jacob S, Murai H, Utsugisawa K, Nowak RJ, Wiendl H, Fujita KP, O'Brien F, Howard JF Jr. Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Ther Adv Neurol Disord. 2020 May 6;13:1756286420911784. doi: 10.1177/1756286420911784. eCollection 2020. PubMed 32426038 ↗
  • Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020 Jul;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y. Epub 2020 Mar 18. PubMed 32189108 ↗
  • Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019 Aug;28(8):2247-2254. doi: 10.1007/s11136-019-02148-2. Epub 2019 Mar 23. Erratum In: Qual Life Res. 2019 Aug;28(8):2255. doi: 10.1007/s11136-019-02204-x. PubMed 30905021 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Feb 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 2 years after primary completion. A results delay was requested in Mar 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2013
First posted
Nov 28, 2013
Start
Dec 2013
Primary completionActual
Feb 2016
CompletionActual
Jun 2016
Results delay requested
Mar 1, 2017
Results first posted
Feb 7, 2018
Last update
Jul 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01997229
Responsible party
Sponsor
First posted
Nov 28, 2013
Start date
Dec 2013
Primary completion
Feb 2016
Completion
Jun 2016
Results posted
Feb 7, 2018
Last update
Jul 16, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion